English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and study aim: Cholangiocarcinoma (CCA) is a rarely curable cancer and is infrequently diagnosed early. There is a ‎growing interest in evaluating CCA biomarkers in serum and bile.  CCA cells express insulin-like growth ‎factor-I (IGF-I) which modulates cell growth and reduces apoptosis.‎ The aim of this study is to evaluate biliary and serum IGF-I as diagnostic biomarkers in patients with extrahepatic ‎cholangio-carcinoma vs. benign biliary obstruction‎‎‎‎. Patients and Method: We conducted a prospective cross-sectional study on 60 patients with extrahepatic biliary obstruction ‎divided into: CCA group (n=30) and benign obstruction (n=30). All patients had diagnostic and therapeutic ‎ERCP with IGF-I assessment in serum and bile‎‎.‎ Results: The CCA group mean age was significantly higher than the benign obstruction group (69.0±4.68 vs. ‎‎56.0±6.47years, p˂0.001). The etiologies of benign biliary obstruction were bile duct stones (n=18), benign ‎stricture (n=11) and cholangitis (n=2). The mean biliary IGF-I in CCA patients was significantly higher (19-‎‎20 folds) than the benign biliary obstruction group (639.14±86.77 vs. 33.60±8.75, p˂0.001). The mean ‎serum IGF-I in the CAA group was higher than the benign group, however, this was non-significant ‎‎(223.06±76.53 vs. 198.34±38.74, p=0.192). Biliary IGF-I cutoff of 292.24ng/ml in CCA vs. benign group ‎showed 100% sensitivity and specificity (AUC=1, p=<0.001). While a serum IGF-I cutoff of 236.32ng/mL ‎in CCA vs. benign group showed a sensitivity/ specificity of 50%/80% respectively (AUC=0.614, p=0.081)‎. Conclusion: Biliary but not serum IGF-I was an excellent marker in differentiating extrahepatic CCA from extrahepatic ‎benign biliary obstruction with a 100% sensitivity and specificity. The diagnostic utility of serum IGF-I in ‎biliary malignancies needs further study‎ ‎‎.

Is Insulin-Like Growth Factor-I (IGF-I) efficient as a Diagnostic ‎Biomarker in Differentiating Cholangiocarcinoma from Benign ‎Biliary Obstruction?‎‎